Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Stroke. 2007;38:1104-1109
Published online before print January 25, 2007, doi: 10.1161/01.STR.0000258347.19449.0f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/1104    most recent
01.STR.0000258347.19449.0fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanossian, N.
Right arrow Articles by Ovbiagele, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanossian, N.
Right arrow Articles by Ovbiagele, B.
Related Collections
Right arrow Other Stroke Treatment - Medical

(Stroke. 2007;38:1104.)
© 2007 American Heart Association, Inc.

Comments, Opinions, and Reviews

High-Density Lipoprotein Cholesterol

An Emerging Target for Stroke Treatment

Nerses Sanossian, MD; Jeffrey L. Saver, MD; Mohamad Navab, PhD Bruce Ovbiagele, MD

From the Department of Neurology (N.S.), University of Southern California, Los Angeles, Calif; the Stroke Center and Department of Neurology (J.L.S., B.O.), University of California Los Angeles (UCLA) Medical Center, Los Angeles, Calif; the Department of Medicine (M.N.), UCLA Medical Center, Los Angeles, Calif; and the Department of Neurology (B.O.), Olive View UCLA Medical Center, Los Angeles, Calif.

Correspondence to Nerses Sanossian, MD, Department of Neurology, University of Southern California, 1200 N State St, #5640, Los Angeles, CA 90033. E-mail sanossia{at}yahoo.com

Background and Purpose— This review characterizes the current state of knowledge of high-density lipoprotein (HDL) in relation to stroke.

Summary of Review— HDL has anti-atherosclerotic and anti-inflammatory properties and is an important component in atherosclerosis. Serum HDL-cholesterol levels are inversely related to heart disease and stroke risk. There are various established and experimental treatments which can raise serum HDL cholesterol and improve its function.

Conclusion— HDL is an emerging target for atherosclerotic stroke treatment with the potential to dramatically impact the care of stroke patients.


Key Words: cholesterol • lipids & lipoprotein • stroke




This article has been cited by other articles:


Home page
 Eur Heart JHome page
A. Murray, C. Cluett, S. Bandinelli, A. M. Corsi, L. Ferrucci, J. Guralnik, A. Singleton, T. Frayling, and D. Melzer
Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people
Eur. Heart J., July 2, 2009; 30(14): 1711 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
F. M. Sacks, L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G. Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, et al.
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
J. Lipid Res., May 1, 2009; 50(5): 894 - 907.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole
Association of diabetes, homocysteine, and HDL with cognition and disability after stroke
Neurology, November 27, 2007; 69(22): 2054 - 2062.
[Abstract] [Full Text] [PDF]


Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.